Welcome to our dedicated page for GRAIL news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on GRAIL stock.
GRAIL reports news on its healthcare business focused on early cancer detection through the Galleri multi-cancer early detection blood test. The company uses next-generation sequencing, population-scale clinical studies, machine learning, software and automation within a targeted methylation-based platform designed to detect and identify multiple cancer types in earlier stages.
Recurring updates include Galleri revenue and test-volume trends, clinical data from programs such as NHS-Galleri and PATHFINDER 2, regulatory and evidence-generation activity, health-system access initiatives, commercial partnerships, conference presentations, equity incentive grants and governance changes. Company announcements also describe how its platform may support screening and precision oncology uses, including risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring and recurrence monitoring.
GRAIL (Nasdaq: GRAL) reported Q2 2024 financial results, showing 43% year-over-year revenue growth to $32.0 million. The company faced a net loss of $1.59 billion, including a $1.42 billion goodwill and intangible impairment. GRAIL's adjusted gross profit increased 66% to $16.0 million, while adjusted EBITDA was $(139.4) million.
Key highlights include enrollment in the REACH study, completion of PATHFINDER 2 study enrollment, and final study visits for the NHS-Galleri trial. GRAIL announced a strategic restructuring, reducing headcount by 30% and focusing on core multi-cancer early detection priorities. These measures are expected to extend the company's cash runway into 2028 and reduce burn to $325 million in 2025.
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced it will release its second quarter 2024 financial results on Tuesday, August 13, 2024, after market close. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and business progress.
Investors and interested parties can access the live webcast and recorded replay through the investor relations section of GRAIL's website at investors.grail.com. Registration for the teleconference is available at https://grail-q2-financial-results-2024.open-exchange.net/. Participants are advised to register and join the webcast at least ten minutes before the scheduled start time to ensure timely connection.
GRAIL (Nasdaq: GRAL) has announced the enrollment of the first participant in the REACH study, evaluating the clinical impact of its Galleri® multi-cancer early detection (MCED) test in the Medicare population. The study, conducted at Community Health Network in Indiana, aims to enroll up to 50,000 Medicare beneficiaries across 50 sites, with a focus on including diverse and underrepresented populations.
The three-year study will compare participants receiving usual care plus an annual Galleri test to those receiving usual care alone. It will assess the reduction in diagnosed stage IV cancers, safety, and healthcare resource utilization associated with Galleri use. The study is FDA-approved and covered by Medicare for participants. This initiative addresses a critical need, as nearly 70% of cancer deaths in the US occur in people aged 65 and older.
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England.
Results from the first 25,000 PATHFINDER 2 participants are expected in the second half of 2025, while final results from the NHS-Galleri trial are anticipated in 2026. These studies aim to expand GRAIL's clinical validation and performance evidence for the Galleri test, with a focus on diverse participant populations. The data will support GRAIL's premarket approval application to the FDA, which is currently in process under a Breakthrough Device Designation.